agilon health (AGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 2, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 1, 2026.
Voting matters and shareholder proposals
Election of three Class II directors: Diana McKenzie, Karen Mcloughlin, and Ron Williams.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from agilon health
- Q2 2026 delivered strong revenue growth and profitability, prompting raised full-year guidance.AGL
Q2 2026 - Cost trends are improving as growth, clinical initiatives, and payer negotiations drive future performance.AGL
2024 Wells Fargo Healthcare Conference - Directors reelected, auditor ratified, and executive pay approved with no shareholder questions.AGL
AGM 2026 - Profitability surged in Q1 2026, prompting raised full-year guidance for key metrics.AGL
Q1 2026 - Tim O'Rourke named CEO and Director with new compensation terms; no changes to voting matters.AGL
Proxy filing - Proxy covers director elections, auditor ratification, pay-for-performance, and ESG priorities.AGL
Proxy filing - Shareholders approved a reverse stock split and adjournment proposal, both backed by the Board.AGL
EGM 2026 - 2026 guidance targets breakeven EBITDA and $5.5B revenue after cost discipline and transformation.AGL
Q4 2025 - Q3 revenue up 28% to $1.45B, but net loss widened to $118M and guidance was lowered.AGL
Q3 2024